DrugPatentWatch Database Preview

AVASTIN Drug Profile

Email this page to a colleague

« Back to Dashboard

Summary for Tradename: AVASTIN

Patents:	934
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for AVASTIN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AVASTIN

Recent Clinical Trials for AVASTIN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Northwestern University	Phase 1
Fourth Military Medical University	Phase 2/Phase 3
Anne Noonan	Phase 1

See all AVASTIN clinical trials

Recent Litigation for AVASTIN

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD.	2019-07-12
Genentech, Inc. v. Pfizer Inc.	2019-04-05
Genentech, Inc. v. Immunex Rhode Island Corp.	2019-03-29

See all AVASTIN litigation

PTAB Litigation

Petitioner	Date
	2018-01-08
	2018-01-05
	2017-03-10

See all AVASTIN litigation

Pharmacology for AVASTIN

Mechanism of Action

Vascular Endothelial Growth Factor Receptor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions

Company Disclosures: US Patents for AVASTIN

These patents were extracted from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26		Athena Neurosciences, Inc. (South San Francisco, CA)	2014-01-25	RX	Orphan	company
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26		Biogen, Inc. (Cambridge, MA)	2020-08-05	RX	Orphan	company
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	002	2004-02-26		Athena Neurosciences, Inc. (South San Francisco, CA)	2014-01-25	RX	Orphan	company
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	002	2004-02-26		Biogen, Inc. (Cambridge, MA)	2020-08-05	RX	Orphan	company

Patent Text Search: US Patents for AVASTIN

These patents were identified by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26		IMMATICS BIOTECHNOLOGY GMBH (Tuebingen, DE)	2035-03-27	RX	Orphan	search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26		SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR)	2032-09-12	RX	Orphan	search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26		IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)	2035-12-11	RX	Orphan	search
Genentech	AVASTIN	bevacizumab	VIAL; INTRAVENOUS	125085	001	2004-02-26		Oncomatryx Biopharma, S.L. (Derio, ES)	2034-02-06	RX	Orphan	search

International Patents for AVASTIN

Country	Patent Number	Estimated Expiration
China	107624118
Canada	2982270
South Korea	101697444
World Intellectual Property Organization (WIPO)	2006091871

Supplementary Protection Certificates for AVASTIN

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1590004-6	Sweden		PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808
132016000070123	Italy		PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
300822	Netherlands		PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 - UITVOERINGSBESLUIT C(2014)2048 20140326
2014C/037	Belgium		PRODUCT NAME: PACLITAXEL DANS UNE FORMULATION DE NANOPARTICULE LIEES A L'ALBUMINE; AUTHORISATION NUMBER AND DATE: EU/1/07/428 20131230